Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342572 · ClinicalTrials.gov registry record · Phase 1
Intra-arterial Chemotherapy for Retinoblastoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04342572: Completed Phase 1 study, sponsored by Washington University School of Medicine.
NCT04342572 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04342572, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.
Primary Outcome
-Feasibility is defined as the ability to receive 3 intra-arterial injections of melphalan per patient.
Interventions
- DRUG Melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 1 |
What the finished NCT04342572 record still lists
NCT04342572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Melphalan is the first listed.
NCT04342572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04342572 about?
NCT04342572 is a clinical study titled "Intra-arterial Chemotherapy for Retinoblastoma". Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.
What is the current status of trial NCT04342572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-08-11. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT04342572?
The interventions under investigation include: Melphalan (DRUG).
Who is sponsoring clinical trial NCT04342572?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04342572's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI